HYD LLC. for Cancer Research and Drug Development was established for the research, development and worldwide marketing of pharmaceutical and consumer products based on the proprietory procedure, deuterium depletion, primarily for the prevention and treatment of various kinds of cancer and for exploration of new indication fields for the application of deuterium depleted water (DDW). Different applications of deuterium depletion are protected by international patents.
In the early nineties, Hungarian molecular biologist, Gábor Somlyai, PhD recognized, that the shortage of deuterium can cause significant changes in living organisms. The most important outcome of his research carried out with deuterium depleted water (DDW) was that tumour cells proved to be extremely sensitive to the withdrawal of deuterium (D). Deuterium depletion is a completely original approach to inhibit the growth of cancer cells in the body and according to the latest results it can also influence other physiological processes like glucose metabolism.
Recently, pharmacological industry started to develop and commercialize deuterium-containing medicines. Strategic replacement of hydrogen atoms in therapeutics with deuterium could positively influence efficacy and side effect profiles of drugs.
HYD's approach to deuterium depletion of water and other molecules has broad potential to enhance the effectiveness of the presently available oncotherapies and result in innovative new medicines and consumer products for the treatment and prevention of cancer and other (e.g. metabolic) diseases.